S100A9 Inhibition Mediates Aerobic Exercise Benefits in Pulmonary Hypertension
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.049578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Zhu Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine Central South University Zhuzhou Hunan China. Hauptthemen laut MEDLINE: Calgranulin B, Hypertension, Pulmonary, Physical Conditioning, Animal. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Previous research has highlighted aerobic exercise as beneficial for patients with pulmonary hypertension (PH) and it is often recommended as a key therapeutic approach. However, the specific mechanisms behind these benefits are not yet fully understood.
Methods
A murine model of hypoxia‐induced PH was developed, and the mice underwent 4 weeks of exercise training. The underlying mechanisms were elucidated by utilizing transcriptomic sequencing, in situ immunofluorescence, flow cytometry, cell culture, in vivo mouse experiments, and clinical cohort.
Results
Aerobic exercise effectively improved hypoxia‐induced pulmonary vascular and right ventricular remodeling. Transcriptomic profiling revealed a marked suppression of inflammatory pathways, with S100A9 identified as the most significantly regulated factor. Under physiological conditions, S100A9 expression is minimal and largely restricted to lung neutrophils; however, hypoxia induces its robust upregulation and widespread distribution, while remaining predominantly neutrophil‐associated. Elevated S100A9 promoted immune cell recruitment and impaired pulmonary artery smooth muscle cell function via activation of the TLR4‐MyD88‐ERK signaling pathway, whereas pharmacological inhibition of S100A9 reduced immune infiltration and restored pulmonary artery smooth muscle cell function. Furthermore, increased S100A9 expression was validated in pulmonary fibrosis–induced PH and in patients with chronic obstructive pulmonary disease associated with PH. The benefits of aerobic exercise in chronic obstructive pulmonary disease associated with PH may be mediated by S100A9 downregulation.
Conclusions
These findings suggest that aerobic exercise alleviates PH by suppressing S100A9‐mediated inflammation and vascular remodeling, identifying S100A9 as a biomarker and therapeutic target, and supporting combined exercise rehabilitation and S100A9‐targeted therapy for group 3 PH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine Central South University Zhuzhou Hunan China.
- Institute for Future Sciences University of South China Changsha Hunan China.
- Department of Respiratory Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine Central South University Zhuzhou Hunan China.
ORCID-Profile: Ziyu He, Yajie Chen, Zhi Liu, Yujuan Huang, Yuan Guo
Zitieren
APA
Chen, Z., He, Z., Liu, X., Chen, Y., Zhou, Q., Liu, Z., Chen, F., Huang, Y., Wang, C., Bai, Z., & Guo, Y. (2026). S100A9 Inhibition Mediates Aerobic Exercise Benefits in Pulmonary Hypertension. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.049578
Vancouver
Chen Z, He Z, Liu X, Chen Y, Zhou Q, Liu Z, et al. S100A9 Inhibition Mediates Aerobic Exercise Benefits in Pulmonary Hypertension. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.049578
BibTeX
@article{Chen2026,
author = {Chen, Zhu and He, Ziyu and Liu, Xiaohan and Chen, Yajie and Zhou, Qianhui and Liu, Zhi and Chen, Fengling and Huang, Yujuan and Wang, Chengming and Bai, Zhuojun and Guo, Yuan},
title = {S100A9 Inhibition Mediates Aerobic Exercise Benefits in Pulmonary Hypertension},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.049578}
}
EUVIMED